Extraction and purification of a novel hemocyanin through implementation of new technologies.

点击翻译按钮获取中文摘要

"Mikota Ltd is looking to build on early investigative work into hemocyanin from the blood of the slipper limpet, an invasive, non-native species to UK shores. Having successfully identified hemocyanin proteins in the limpets as well as drafted and tested a basic extraction protocol, Mikota now aims to scale up production of this hemocyanin to a commercial level. As well as scaling up production, we will focus on perfecting a storage method for the finished product that will preserve the viability of the hemocyanin for long term storage.This work is being undertaken in collaboration with Cardiff University, with their work packages being led by Dr Mark Young and Prof Thomas Wirth. In support of Cardiff University work, and Mikota's helping young people prepare for the work place, Mikota is funding 3 Professional Year students to be placed at Cardiff University.By scaling up this process Mikota will deliver a new sustainable medical grade hemocyanin sourced locally from an invasive species to the UK, that has significant value in the anticancer, vaccine and immunotherapy markets."